Clinical Research Directory
Browse clinical research sites, groups, and studies.
Glucose-lowering Drugs as an Adjunct to Insulin Therapy in Chinese Patients With Type 1 Diabetes
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Summary
To assess the real-world impact of glucose-lowering drugs (GLDs) as an adjunct to insulin in Chinese patients with type 1 diabetes (T1DM). Does glucose-lowering drugs (GLDs) as an adjunct to insulin improve clinical outcomes in Chinese patients with type 1 diabetes (T1DM) when used long-term in real-world practice?
Official title: Effectiveness and Safety of Glucose-lowering Drugs as an Adjunct to Insulin Therapy in Chinese Patients With Type 1 Diabetes: a Retrospective, Observational Study
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
OBSERVATIONAL
Enrollment
500
Start Date
2026-05-01
Completion Date
2027-12-31
Last Updated
2026-02-17
Healthy Volunteers
No
Conditions
Interventions
GLD+insulin group
The glucose-lowering drugs included in the analysis were metformin, acarbose and DPP-4i alone or in combination with other agents.